Brief: Cassava Sciences Reports Q2 2023 Financial Results And Operating Updates
Cassava Sciences Inc SAVA.O :
* CASSAVA SCIENCES REPORTS Q2 2023 FINANCIAL RESULTS AND
OPERATING
UPDATES
* CASSAVA SCIENCES INC Q2 LOSS PER SHARE $0.63
* CASSAVA SCIENCES INC - NET CASH USE IN SECOND HALF 2023 IS
EXPECTED TO BE $40 TO $50 MILLION
Source text for Eikon: ID:nGNX1n2HPj
Further company coverage: SAVA.O
Recent news on Filana Therapeutics
See all newsCassava Sciences says US DOJ has closed investigation into company (updated)
Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing